273 related articles for article (PubMed ID: 33387481)
1. Comparative metabolomics reveals key pathways associated with the synergistic activity of polymyxin B and rifampicin combination against multidrug-resistant Acinetobacter baumannii.
Zhao J; Han ML; Zhu Y; Lin YW; Wang YW; Lu J; Hu Y; Tony Zhou Q; Velkov T; Li J
Biochem Pharmacol; 2021 Feb; 184():114400. PubMed ID: 33387481
[TBL] [Abstract][Full Text] [Related]
2. Model-informed dose optimisation of polymyxin-rifampicin combination therapy against multidrug-resistant Acinetobacter baumannii.
Zhao J; Zhu Y; Han ML; Lu J; Yu HH; Wickremasinghe H; Zhou QT; Bergen P; Rao G; Velkov T; Lin YW; Li J
Int J Antimicrob Agents; 2023 Sep; 62(3):106902. PubMed ID: 37380093
[TBL] [Abstract][Full Text] [Related]
3. In-vitro activity of polymyxin B in combination with imipenem, rifampicin and azithromycin versus multidrug resistant strains of Acinetobacter baumannii producing OXA-23 carbapenemases.
Wareham DW; Bean DC
Ann Clin Microbiol Antimicrob; 2006 Apr; 5():10. PubMed ID: 16630352
[TBL] [Abstract][Full Text] [Related]
4. Anthelmintic closantel enhances bacterial killing of polymyxin B against multidrug-resistant Acinetobacter baumannii.
Tran TB; Cheah SE; Yu HH; Bergen PJ; Nation RL; Creek DJ; Purcell A; Forrest A; Doi Y; Song J; Velkov T; Li J
J Antibiot (Tokyo); 2016 Jun; 69(6):415-21. PubMed ID: 26669752
[TBL] [Abstract][Full Text] [Related]
5. Synergistic effect between nisin and polymyxin B against pandrug-resistant and extensively drug-resistant Acinetobacter baumannii.
Thomas VM; Brown RM; Ashcraft DS; Pankey GA
Int J Antimicrob Agents; 2019 May; 53(5):663-668. PubMed ID: 30880230
[TBL] [Abstract][Full Text] [Related]
6. Mechanisms Underlying Synergistic Killing of Polymyxin B in Combination with Cannabidiol against
Hussein M; Allobawi R; Levou I; Blaskovich MAT; Rao GG; Li J; Velkov T
Pharmaceutics; 2022 Apr; 14(4):. PubMed ID: 35456620
[TBL] [Abstract][Full Text] [Related]
7. In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii.
Yoon J; Urban C; Terzian C; Mariano N; Rahal JJ
Antimicrob Agents Chemother; 2004 Mar; 48(3):753-7. PubMed ID: 14982760
[TBL] [Abstract][Full Text] [Related]
8. Polymyxin-resistant, carbapenem-resistant Acinetobacter baumannii is eradicated by a triple combination of agents that lack individual activity.
Lenhard JR; Thamlikitkul V; Silveira FP; Garonzik SM; Tao X; Forrest A; Soo Shin B; Kaye KS; Bulitta JB; Nation RL; Li J; Tsuji BT
J Antimicrob Chemother; 2017 May; 72(5):1415-1420. PubMed ID: 28333347
[TBL] [Abstract][Full Text] [Related]
9. Global metabolic analyses identify key differences in metabolite levels between polymyxin-susceptible and polymyxin-resistant Acinetobacter baumannii.
Maifiah MH; Cheah SE; Johnson MD; Han ML; Boyce JD; Thamlikitkul V; Forrest A; Kaye KS; Hertzog P; Purcell AW; Song J; Velkov T; Creek DJ; Li J
Sci Rep; 2016 Feb; 6():22287. PubMed ID: 26924392
[TBL] [Abstract][Full Text] [Related]
10. Polymyxin combination therapy for multidrug-resistant, extensively-drug resistant, and difficult-to-treat drug-resistant gram-negative infections: is it superior to polymyxin monotherapy?
Ardebili A; Izanloo A; Rastegar M
Expert Rev Anti Infect Ther; 2023 Apr; 21(4):387-429. PubMed ID: 36820511
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Killing of Polymyxin B in Combination With the Antineoplastic Drug Mitotane Against Polymyxin-Susceptible and -Resistant
Tran TB; Bergen PJ; Creek DJ; Velkov T; Li J
Front Pharmacol; 2018; 9():359. PubMed ID: 29713282
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of polymyxin B, rifampicin, tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii in Singapore.
Lim TP; Tan TY; Lee W; Sasikala S; Tan TT; Hsu LY; Kwa AL
PLoS One; 2011 Apr; 6(4):e18485. PubMed ID: 21533030
[TBL] [Abstract][Full Text] [Related]
13. Untargeted metabolomics analysis reveals key pathways responsible for the synergistic killing of colistin and doripenem combination against Acinetobacter baumannii.
Maifiah MH; Creek DJ; Nation RL; Forrest A; Tsuji BT; Velkov T; Li J
Sci Rep; 2017 Mar; 7():45527. PubMed ID: 28358014
[TBL] [Abstract][Full Text] [Related]
14. Origanum vulgare essential oil: antibacterial activities and synergistic effect with polymyxin B against multidrug-resistant Acinetobacter baumannii.
Amaral SC; Pruski BB; de Freitas SB; Allend SO; Ferreira MRA; Moreira C; Pereira DIB; Junior ASV; Hartwig DD
Mol Biol Rep; 2020 Dec; 47(12):9615-9625. PubMed ID: 33190200
[TBL] [Abstract][Full Text] [Related]
15. Comparative Metabolomics Reveals Key Pathways Associated With the Synergistic Killing of Colistin and Sulbactam Combination Against Multidrug-Resistant
Han ML; Liu X; Velkov T; Lin YW; Zhu Y; Creek DJ; Barlow CK; Yu HH; Zhou Z; Zhang J; Li J
Front Pharmacol; 2019; 10():754. PubMed ID: 31333468
[No Abstract] [Full Text] [Related]
16. Comparison of in vitro synergy between polymyxin B or colistin in combination with 16 antimicrobial agents against multidrug-resistant Acinetobacter baumannii isolates.
Wang Y; Ma Y; Xiong L; Wang X; Zhou Y; Chi X; Chen T; Fu H; Luo Q; Xiao Y
J Microbiol Immunol Infect; 2024 Apr; 57(2):300-308. PubMed ID: 38350840
[TBL] [Abstract][Full Text] [Related]
17. Pharmacodynamic Effects of Sulbactam/Meropenem/Polymyxin-B Combination Against Extremely Drug Resistant
Menegucci TC; Fedrigo NH; Lodi FG; Albiero J; Nishiyama SAB; Mazucheli J; Carrara-Marroni FE; Voelkner NMF; Gong H; Sy SKB; Tognim MCB
Microb Drug Resist; 2019 Nov; 25(9):1266-1274. PubMed ID: 31216222
[No Abstract] [Full Text] [Related]
18. Determination of in vitro activities of polymyxin B and rifampin in combination with ampicillin/sulbactam or cefoperazone/sulbactam against multidrug-resistant Acinetobacter baumannii by the E-test and checkerboard methods.
Cetin ES; Tekeli A; Ozseven AG; Us E; Aridogan BC
Jpn J Infect Dis; 2013; 66(6):463-8. PubMed ID: 24270131
[TBL] [Abstract][Full Text] [Related]
19. Polymyxin B in combination with doripenem against heteroresistant Acinetobacter baumannii: pharmacodynamics of new dosing strategies.
Rao GG; Ly NS; Bulitta JB; Soon RL; San Roman MD; Holden PN; Landersdorfer CB; Nation RL; Li J; Forrest A; Tsuji BT
J Antimicrob Chemother; 2016 Nov; 71(11):3148-3156. PubMed ID: 27494922
[TBL] [Abstract][Full Text] [Related]
20. Metabolomics Study of the Synergistic Killing of Polymyxin B in Combination with Amikacin against Polymyxin-Susceptible and -Resistant Pseudomonas aeruginosa.
Hussein M; Han ML; Zhu Y; Zhou Q; Lin YW; Hancock REW; Hoyer D; Creek DJ; Li J; Velkov T
Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
